Jason Gotlib

Publications

• When yellow jackets attack: Recurrent and severe anaphylactic reactions to insect bites and stings. Pollyea DA, George TI, Corless C, Gotlib J. Am J Hematol. 2009
• Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH. Proc Natl Acad Sci U S A. 2009; 106 (10): 3925-9
• RNAi screen for rapid therapeutic target identification in leukemia patients. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. Proc Natl Acad Sci U S A. 2009; 106 (21): 8695-700
• Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A. Leukemia. 2009; 23 (9): 1587-97
• On being metachromatic: Mystique and misunderstanding in mastocytosis. Gotlib J, Am J Hematol. 2009
• Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nat Med. 2009; 15 (5): 566-71
• Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA. Blood. 2009; 113 (9): 1906-8
• A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL. Am J Hematol. 2009; 84 (1): 15-20
• Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. Medeiros BC, Gotlib J, Zehnder J. Leuk Lymphoma. 2009; 50 (5): 851-3
• Gene expression and pathway analysis of immune thrombocytopenic purpura. Sood R, Wong W, Gotlib J, Jeng M, Zehnder JL. Br J Haematol. 2008; 140 (1): 99-103
• Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH. Cancer Cell. 2008; 13 (4): 321-30
• Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Gotlib J, Cools J. Leukemia. 2008; 22 (11): 1999-2010
• Chronic eosinophilic leukemia/hypereosinophilic syndrome. Gotlib J, Cancer Treat Res. 2008: 142 69-106
• Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, Zehnder JL. J Mol Diagn. 2006; 8 (3): 330-4
• KIT mutations in mastocytosis and their potential as therapeutic targets. Gotlib J, Immunol Allergy Clin North Am. 2006; 26 (3): 575-92
• Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Gotlib J, Cross NC, Gilliland DG. Best Pract Res Clin Haematol. 2006; 19 (3): 535-69
• A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. Fukumoto JS, Gotlib J. Am J Hematol. 2006; 81 (11): 870-4
• Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. Dormady SP, Mariappan MR, Kao D, Gotlib J. J Clin Oncol. 2006; 24 (27): 4515-6
• Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Gotlib J, Acta Haematol. 2005; 114 (1): 7-25
• Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE. Blood. 2005; 106 (8): 2865-70
• Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Gotlib J, Curr Hematol Rep. 2005; 4 (1): 77-84
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S, Gotlib J. Semin Cancer Biol. 2004; 14 (1): 23-31
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. N Engl J Med. 2004; 351 (7): 657-67
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S, Gotlib J. Semin Cancer Biol. 2004; 14 (4): 307-15
• The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutré SE. Blood. 2004; 103 (8): 2879-91